Management of patients with low-risk papillary thyroid carcinoma

Endocrine Practice

Volumn 13, Issue 5, 2007, Pages 521-533

  Hay, Ian D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; MORTALITY; PAPILLARY CARCINOMA; REVIEW; RISK FACTOR; THYROID TUMOR; THYROIDECTOMY; TUMOR RECURRENCE;

CARCINOMA, PAPILLARY; HUMANS; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 35148882555     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.5.521     Document Type: Review

References (55)

1. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Amer Clin Climatol Assoc. 2002;113:241-260.
2. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088-1095.
3. Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am. 1990;19:545-576.
4. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-1057.
5. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy and outcome. Mayo Clin Proc. 1986;61:978-996.
6. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879-885.
7. Cady B. Seminars in surgical oncology on thyroid cancer. J Surg Oncol. 2006;94:646-648.
8. Schlumberger M, Filetti S, Hay ID. Nontoxic goiter and thyroid neoplasia. In : Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology. 10th ed. Philadelphia, PA: W.B. Saunders Company, 2003:457-90.
9. Sutton RT, Reading CC, Charboneau JW, James EM, Grant CS, Hay ID. US-guided biopsy of neck masses in postoperative assessment of patients with thyroid cancer. Radiology. 1988;168:769-772.
10. Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol. 2002;37:169-174.
11. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-3885.
12. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid. 2002;12:37-43.
13. Sherman SI, Angelos P, Ball DW, et al. Thyroid carcinoma. J Natl Compr Canc Netw. 2007;5:568-621.
14. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2000;86:1467-1473.
15. Wartofsky L. Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid cancer without diagnostic (131)I scanning. J Clin Endocrinol Metab. 2002;87:1486-1489.
16. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report on the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-1441.
17. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
18. Grant CS, Hay ID, Gough IR, McCarthy PM, Goellner JR. Long-term follow-up of patients with benign thyroid fine-needle aspiration cytologic diagnoses. Surgery.1989;106:980-986.
19. Mai KT, Landry DC, Thomas J, Yazdi HM, Perkins DG, Odell PF. Ret oncogene protein expression in papillary thyroid carcinoma and related lesions. Tumori. 2001;87:166-172.
20. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol. 2002;26:41-44.
21. Hunt JL, LiVolsi VA, Baloch ZW, et al. Anovel microdis- A novel microdissection and genotyping of follicular-derived thyroid tumors to predict aggressiveness. Hum Pathol. 2003;34:375-380.
22. Grebe SK, Hay ID. Follicular thyroid cancer. Endocrinol Metab Clin North Am. 1995;24:761-801.
23. Grant CS, Hay ID, Gough IR, Bergstralh EF, Goellner JR, McConahey WM. Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery. 1988;104:954-962.
24. Zimmerman D, Hay ID, Gough IR, et al. Papillary thyroid carcinoma in children and adults: long-term follow-up of 1039 consecutive patients conservatively treated at one institution during three decades. Surgery. 1988;104:1157-1166.
25. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139-1146.
26. Grebe SKG, Hay ID. The role of surgery in the management of differentiated thyroid cancer. J Endocrinol Invest. 1997;20:32-35.
27. Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery. 1998;124:958-964.
28. Hay ID, Bergstralh EJ, Grant CS, et al. Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989. Surgery. 1999;126:1173-1181.
29. Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract. 2001;7:202-220.
30. DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press, 2004: 1-320.
31. Stulak JM, Grant CS, Farley DR, et al. Value of pre-operative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141:489-494.
32. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery. 2006;140:1000-1005.
33. Palazzo FF, Gosnell J, Savio R, et al. Lymphadenectomy for papillary thyroid cancer: changes in practice over four decades. Eur J Surg Oncol. 2006:32:340-344.
34. Davies T. Personalized thyroid medicine-the time is now. Thyroid. 2007;17:1.
35. Doherty GM. Routine central neck lymph node dissection for thyroid carcinoma. Surgery. 2006;140:1007-1008.
36. Sisson JC. Applying the radioactive eraser: I-131 to ablate normal thyroid tissue in patients from whom thyroid cancer has been resected. J Nucl Med. 1983; 24:743-745.
37. Dobert N, Menzel C, Oeschger S, Grunwald G. Differentiated thyroid carcinoma: the new UICC 6th edition TNM classification system in a retrospective analysis of 169 patients. Thyroid. 2004;14:65-70.
38. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab. 2004;89:3713-3720.
39. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947-953.
40. Cooper DS, Doherty GM, Haugen BR, et al, (the American Thyroid Association Guidelines Taskforce). Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142.
41. Cady B. Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, riskgroup assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Amer J Surg. 1997;174:462-468.
42. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006;94:692-700.
43. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668-3676.
44. Varma VM, Beierwaltes WH, Nofal H, Nishiyama RH, Copp JE. Treatment of thyroid cancer. Death rates after surgery and after surgery followed by sodium iodide I-131. JAMA. 1970;214:1437-1442.
45. Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore). 1977;56:171-196.
46. Brierley J, Tsang R, Panzarella T, Bana N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf). 2005;63:418-427.
47. Jonklaas J, Sarlis N, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229-1242.
48. Pacini F, Schlumberger M, Harmer C, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol. 2005;153:651-659.
49. Pacini F, Schlumberger M, Dralle H et al. European Consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium [erratum in Eur J Endocrinol. 2006;155:385]. Eur J Endocrinol. 2006;154:787-803.
50. British Thyroid Association and Royal College of Physicians. Guidelines for management of thyroid cancer. http://www.british-thyroid- association.org/draft-thyca-23.12.06.pdf. Published 2002. Updated 2006.
51. Hay ID. Papillary thyroid cancer in the twenty first century: a mid-Atlantic perspective one year after the publication of the American Thyroid Association Clinical Management Guidelines. Hot Thyroidology. 2007;1:1-14. http://www.hotthyroidology.com/editorial-166.html.
52. Fatourechi V, Hay ID, Mullan BP, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid. 2000;10: 573-577.
53. Smallridge RC, Meek SE, Morgan MA, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab. 2007;92:82-87.
54. Torlontano M, Attard M, Crocetti U, et al. Follow-up of low-risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab. 2004;89:3402-3407.
55. Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR. Percutaneous ethanol injection for treatment of cervical lymph nodal metastases in patients with papillary carcinoma. AJR Am J Roentgenol. 2002:178:699-704.